Berirab P Mechanism of Action

Pharmacotherapeutic Group: Immune sera and immunoglobulins, human rabies immunoglobulins. ATC-code: J06B B05.
Pharmacology: Pharmacodynamics: Berirab P contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against rabies vaccine.
Pharmacokinetics: Human rabies immunoglobulin for intramuscular administration is bioavailable in the recipient's circulation after a delay of 2 to 3 days.
Human rabies immunoglobulin has a half-life of about 3 to 4 weeks. This half-life may vary from patient to patient.
IgG and IgG-complexes are broken down in cells of the reticuloendothelial system.
Toxicology: Preclinical safety data: Berirab P contains rabies immunoglobulin as active ingredient which is derived from human plasma and acts like endogenous constituent of plasma. Single dose i.m. application of immunoglobulin to various animal species did not reveal toxic effects. Preclinical studies with repeated dose applications (chronic toxicity, cancerogenicity and mutagenicity) cannot be reasonably performed in conventional animal models due to the development of antibodies following the application of heterologous human proteins.